Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2021 - 2025)

Tarsus Pharmaceuticals has reported Other Non Operating Income over the past 5 years, most recently at -$81000.0 for Q1 2025.

  • Quarterly results put Other Non Operating Income at -$81000.0 for Q1 2025, up 55.25% from a year ago — trailing twelve months through Dec 2025 was -$81000.0 (up 96.24% YoY), and the annual figure for FY2024 was -$206000.0, changed.
  • Other Non Operating Income for Q1 2025 was -$81000.0 at Tarsus Pharmaceuticals, down from -$27000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for TARS hit a ceiling of $1.1 million in Q4 2021 and a floor of -$1.9 million in Q2 2024.
  • Median Other Non Operating Income over the past 5 years was -$34000.0 (2021), compared with a mean of -$94933.3.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 208.82% in 2022 and later crashed 3116.67% in 2024.
  • Tarsus Pharmaceuticals' Other Non Operating Income stood at $1.1 million in 2021, then tumbled by 104.35% to -$50000.0 in 2022, then skyrocketed by 170.0% to $35000.0 in 2023, then tumbled by 177.14% to -$27000.0 in 2024, then tumbled by 200.0% to -$81000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$81000.0 (Q1 2025), -$27000.0 (Q4 2024), and -$1.9 million (Q2 2024) per Business Quant data.